NFKB1 and neoplasm: Unlike our expectations, the results in vivo clearly demonstrated that AIMs harbor anti-proliferative, anti-invasive, and anti-angiogenic effects by inhibiting NF-κB activity, although the tumor sizes in control groups vary.